Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus MEDLINE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Rapid COVID-19 vaccine rollout: immense success but challenges ahead.

Title: Rapid COVID-19 vaccine rollout: immense success but challenges ahead.
Authors: Sandmann FG; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, NW9 5EQ, UK. Electronic address: frank.sandmann@phe.gov.uk.; Jit M; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; School of Public Health, University of Hong Kong, Hong Kong Special Administrative Region, China.
Source: The Lancet. Infectious diseases [Lancet Infect Dis] 2022 Mar; Vol. 22 (3), pp. 302-304. Date of Electronic Publication: 2021 Sep 22.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Comment
Language: English
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
Imprint Name(s): Original Publication: New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-
MeSH Terms: COVID-19*/prevention & control ; COVID-19 Vaccines*; Humans ; SARS-CoV-2 ; Vaccination
Competing Interests: FGS and MJ are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health Economics, a partnership between Public Health England (PHE), Imperial College London, and the London School of Hygiene & Tropical Medicine (grant code NIHR200908). MJ was supported by the NIHR HPRU in Immunisation at LSHTM in partnership with PHE (grant reference code NIHR200929). MJ has also received funding from the EU's Horizon 2020 research and innovation programme SC1-PHE-CORONAVIRUS-2020 - project EpiPose (No 101003688). The views expressed in this Comment are those of the authors and not necessarily those of the EU, NIHR, PHE, or the UK Department of Health and Social Care.
Comments: Comment on: Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1.. (PMID: 34562375)
Substance Nomenclature: 0 (COVID-19 Vaccines)
Entry Date(s): Date Created: 20210925 Date Completed: 20220303 Latest Revision: 20220303
Update Code: 20260130
PubMed Central ID: PMC8457758
DOI: 10.1016/S1473-3099(21)00616-2
PMID: 34562376
Database: MEDLINE

Journal Article; Research Support, Non-U.S. Gov't; Comment